Literature DB >> 18707818

Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy.

Maria Pearse1, Richard Choo, Cyril Danjoux, Sandra Gardner, Gerard Morton, Ewa Szumacher, Andrew Loblaw, Patrick Cheung.   

Abstract

PURPOSE: To assess the acute and late gastrointestinal (GI) and genitourinary (GU) toxicity of salvage radiotherapy (RT). METHODS AND MATERIALS: A total of 75 patients with prostate-specific antigen relapse or clinically isolated local recurrence after radical prostatectomy were accrued between 1998 and 2002 for a Phase II study to evaluate the efficacy of salvage RT plus 2-year androgen suppression. Acute and late GI and GU toxicity was prospectively assessed using the National Cancer Institute Expanded Common Toxicity Criteria Version 2. For acute toxicity, prevalence was examined. For late toxicity, cumulative incidences of Grade 2 or higher and Grade 3 toxicity were calculated.
RESULTS: Median age was 67 years at the time of salvage RT. Median time from radical prostatectomy to RT was 36.2 months. Median follow-up was 45.1 months. Seventy-five patients were available for acute toxicity analysis, and 72 for late toxicity. Twelve percent and 40% had preexisting GI and GU dysfunction before RT, respectively. Sixty-eight percent, 21%, and 5% experienced Grade 1, 2, and 3 acute GI or GU toxicity, respectively. Cumulative incidences of Grade 2 or higher late GI and GU toxicity at 36 months were 8.7% and 22.6%, and Grade 3 late GI and GU toxicity, 1.6% and 2.8%, respectively. None had Grade 4 late toxicity. The severity of acute GU toxicity (Grade < 2 vs. >/= 2) was a significant predictor factor for Grade 2 or higher late GU toxicity after adjusting for preexisting GU dysfunction.
CONCLUSION: Salvage RT generally was well tolerated. Grade 3 or higher late GI or GU toxicity was uncommon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707818     DOI: 10.1016/j.ijrobp.2008.05.063

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

Review 1.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.

Authors:  Nitin Ohri; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Eur J Cancer       Date:  2011-09-22       Impact factor: 9.162

2.  Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.

Authors:  Richard Choo
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

3.  Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Authors:  Michael Sia; George Rodrigues; Cynthia Menard; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Michael Milosevic; Padraig Warde; Charles Catton
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  Salvage radiotherapy after radical prostatectomy: Preserving patient quality of life with modern treatment techniques.

Authors:  Martin Korzeniowski
Journal:  Can Urol Assoc J       Date:  2017-12-14       Impact factor: 1.862

5.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

Authors:  Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

6.  Lower Bladder Toxicity of Salvage Versus Adjuvant Modern Radiotherapy for Prostate Cancer Patients.

Authors:  Annamaria Vinciguerra; Antonietta Augurio; Consuelo Rosa; David Fasciolo; Marzia Borgia; Valentina Milone; Michele Marchioni; Marta DI Nicola; Domenico Genovesi; Luciana Caravatta
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 7.  Management of patients with biochemical recurrence after local therapy for prostate cancer.

Authors:  Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci
Journal:  Hematol Oncol Clin North Am       Date:  2013-09-18       Impact factor: 3.722

8.  General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V.

Authors:  Mark Shilkrut; Felix Feng; Daniel A Hamstra
Journal:  Front Oncol       Date:  2012-09-27       Impact factor: 6.244

9.  Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center.

Authors:  Olivier Riou; Pascal Fenoglietto; Benoit Laliberté; Cathy Menkarios; Carmen Llacer Moscardo; Meng Huor Hay; Norbert Ailleres; Jean-Bernard Dubois; Xavier Rebillard; David Azria
Journal:  ISRN Urol       Date:  2012-03-20

Review 10.  Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life.

Authors:  Hamid Raziee; Alejandro Berlin
Journal:  Front Oncol       Date:  2016-03-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.